Skip to main content
Log in

Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The physiologically based pharmacokinetic (PBPK) model for liver transporter substrates has been established previously and used for predicting drug–drug interactions (DDI) and for clinical practice guidance. So far, nearly all the published PBPK models for liver transporter substrates have one or more hepatic clearance processes (i.e., active uptake, passive diffusion, metabolism, and biliary excretion) estimated by fitting observed systemic data. The estimated hepatic clearance processes are then used to predict liver concentrations and DDI involving either systemic or liver concentration. However, the accuracy and precision of such predictions are unclear. In this study, we try to address this question by using the PBPK model to generate simulated compounds for which we know both systemic and liver profiles. We then developed an approach to assess the accuracy and precision of predicted liver concentration. With hepatic clearance processes estimated using plasma data, model predictions of liver are typically accurate (i.e., true value is bounded by predicted maximum and minimum); however, only for a few compounds are predictions also precise. The results of the current study indicate that extra attention is required when using the current PBPK approach to predict liver concentration and DDI for transporter substrates dependent upon liver concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Peters SA. Physiologically based pharmacokinetic (PBPK) modeling and simulations : principles, methods, and applications in the pharmaceutical industry. Hoboken: Wiley; 2011. xvii, 430 p. p.

    Google Scholar 

  2. Rose RH, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M. Application of a physiologically based pharmacokinetic model to predict OATP1B1-related variability in pharmacodynamics of rosuvastatin. CPT Pharmacometrics Syst Pharmacol. 2014;3, e124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652–62.

    Article  CAS  PubMed  Google Scholar 

  4. Li R, Barton HA, Varma MV. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. Clin Pharmacokinet. 2014;53(8):659–78.

    Article  PubMed  Google Scholar 

  5. Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, et al. A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn. 2014;41(3):197–209.

    Article  CAS  PubMed  Google Scholar 

  6. Li R, Barton HA, Maurer TS. Toward prospective prediction of pharmacokinetics in OATP1B1 genetic variant populations. CPT Pharmacometrics Syst Pharmacol. 2014;3, e151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67–86.

    Article  CAS  PubMed  Google Scholar 

  8. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5.

    Article  CAS  PubMed  Google Scholar 

  9. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.

    Article  CAS  PubMed  Google Scholar 

  10. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.

    Article  CAS  PubMed  Google Scholar 

  11. Poirier A, Funk C, Scherrmann JM, Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm. 2009;6(6):1716–33.

    Article  CAS  PubMed  Google Scholar 

  12. Bellu G, Saccomani MP, Audoly S, D’Angio L. DAISY: a new software tool to test global identifiability of biological and physiological systems. Comput Methods Prog Biomed. 2007;88(1):52–61.

    Article  Google Scholar 

  13. Spear RC, Bois FY. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. Environ Health Perspect. 1994;102 Suppl 11:61–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553–63.

    Article  CAS  PubMed  Google Scholar 

  15. DiStefano JJ. Dynamic systems biology modeling and simulation. First edition. ed. Amsterdam: Elsevier, Academic Press; 2013. xxii, 859 pages p.

Download references

Acknowledgments

The authors greatly appreciate the sincere help on structural identifiability analysis from Dr. Nicolette Meshkat at Santa Clara University and Dr. Joe DiStefano III at University of California, Los Angeles.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rui Li.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 267 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, R., Maurer, T.S., Sweeney, K. et al. Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds. AAPS J 18, 746–756 (2016). https://doi.org/10.1208/s12248-016-9895-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-016-9895-0

KEY WORDS

Navigation